165 related articles for article (PubMed ID: 17658669)
1. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A
Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669
[TBL] [Abstract][Full Text] [Related]
2. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.
Nolan SM; Surman SR; Amaro-Carambot E; Collins PL; Murphy BR; Skiadopoulos MH
Vaccine; 2005 Sep; 23(39):4765-74. PubMed ID: 15964103
[TBL] [Abstract][Full Text] [Related]
3. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
[TBL] [Abstract][Full Text] [Related]
4. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
Bartlett EJ; Castaño A; Surman SR; Collins PL; Skiadopoulos MH; Murphy BR
Virol J; 2007 Jul; 4():67. PubMed ID: 17605811
[TBL] [Abstract][Full Text] [Related]
5. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.
Bartlett EJ; Amaro-Carambot E; Surman SR; Collins PL; Murphy BR; Skiadopoulos MH
Vaccine; 2006 Mar; 24(14):2674-84. PubMed ID: 16364511
[TBL] [Abstract][Full Text] [Related]
6. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
[TBL] [Abstract][Full Text] [Related]
7. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
Bartlett EJ; Amaro-Carambot E; Surman SR; Newman JT; Collins PL; Murphy BR; Skiadopoulos MH
Vaccine; 2005 Sep; 23(38):4631-46. PubMed ID: 15951066
[TBL] [Abstract][Full Text] [Related]
8. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
Skiadopoulos MH; Durbin AP; Tatem JM; Wu SL; Paschalis M; Tao T; Collins PL; Murphy BR
J Virol; 1998 Mar; 72(3):1762-8. PubMed ID: 9499025
[TBL] [Abstract][Full Text] [Related]
9. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
[TBL] [Abstract][Full Text] [Related]
11. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
[TBL] [Abstract][Full Text] [Related]
12. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
Skiadopoulos MH; Surman S; Tatem JM; Paschalis M; Wu SL; Udem SA; Durbin AP; Collins PL; Murphy BR
J Virol; 1999 Feb; 73(2):1374-81. PubMed ID: 9882342
[TBL] [Abstract][Full Text] [Related]
13. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
McAuliffe JM; Surman SR; Newman JT; Riggs JM; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2004 Feb; 78(4):2029-36. PubMed ID: 14747567
[TBL] [Abstract][Full Text] [Related]
14. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
[TBL] [Abstract][Full Text] [Related]
15. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
16. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children.
Karron RA; Herbert K; Wanionek K; Schmidt AC; Schaap-Nutt A; Collins PL; Buchholz UJ
J Pediatric Infect Dis Soc; 2023 Apr; 12(3):173-176. PubMed ID: 36594442
[TBL] [Abstract][Full Text] [Related]
18. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.
Subbarao EK; Park EJ; Lawson CM; Chen AY; Murphy BR
J Virol; 1995 Oct; 69(10):5969-77. PubMed ID: 7666501
[TBL] [Abstract][Full Text] [Related]
19. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
[TBL] [Abstract][Full Text] [Related]
20. A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.
Bartlett EJ; Cruz AM; Boonyaratanakornkit J; Esker J; Castaño A; Skiadopoulos MH; Collins PL; Murphy BR; Schmidt AC
Vaccine; 2010 Jan; 28(3):767-79. PubMed ID: 19857454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
